Duodenal Ulcer Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Treatment (Proton Pump Inhibitors, H2 Antagonists, Antibiotics, Other), By Route Of Administration (Oral, Parenteral), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Other), By Region and Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 5.31 Billion
CAGR (2026-2031)	4.34%
Fastest Growing Segment	Proton Pump Inhibitors
Largest Market	North America
Market Size (2031)	USD 6.85 Billion

Market Overview

The Global Duodenal Ulcer Treatment Market will grow from USD 5.31 Billion in 2025 to USD 6.85 Billion by 2031 at a 4.34% CAGR. The Global Duodenal Ulcer Treatment Market consists of therapeutic agents such as proton pump inhibitors, antibiotics, and potassium competitive acid blockers intended to heal mucosal defects in the proximal small intestine. The primary drivers sustaining this market include the extensive consumption of nonsteroidal anti-inflammatory drugs and the persistent global burden of bacterial infections which necessitate continuous pharmaceutical intervention. According to the American Gastroenterological Association, in 2024, the crude global prevalence of Helicobacter pylori infection in adults was reported to be 43.9%. This substantial infection rate ensures a steady baseline of patients requiring eradication therapy to prevent ulcer recurrence and associated complications.

Despite these strong demand indicators, the market encounters a significant impediment regarding the rising rates of antimicrobial resistance which reduces the efficacy of standard therapeutic regimens. This resistance forces clinicians to adopt more complex salvage treatments and increases the difficulty of successful eradication, thereby creating a barrier to effective widespread disease management and potentially constraining the consistent application of standard first line pharmaceutical options.

Key Market Drivers

The Expansion of the Vulnerable Geriatric Population serves as a primary catalyst for the Global Duodenal Ulcer Treatment Market, fundamentally altering the patient demographic and driving sustained demand for therapeutic interventions. As individuals age, gastric mucosal defense mechanisms naturally decline, making the elderly significantly more susceptible to injury from gastric acid and Helicobacter pylori infections. This vulnerability is exacerbated by the higher prevalence of comorbid conditions such as arthritis in older adults, which necessitates the chronic consumption of non-steroidal anti-inflammatory drugs (NSAIDs)—a major risk factor for ulceration. According to the United Nations Population Fund, June 2024, the worldwide share of people aged 65 years and older increased to 10.3% in 2024, representing a rapidly widening base of high-risk patients. This demographic shift ensures a continuous influx of complex cases requiring potent acid-suppression therapies and eradication regimens to prevent recurrence and complications like perforation or bleeding.

Simultaneously, the Development of Novel Therapeutic Agents is reinvigorating the market by addressing the critical limitations of conventional proton pump inhibitors (PPIs), particularly in the face of antibiotic resistance. Pharmaceutical companies are aggressively commercializing potassium-competitive acid blockers (P-CABs), which offer faster onset of action and greater stability in acidic environments compared to traditional therapies. The commercial success of this drug class is evident; according to Takeda Pharmaceutical Company Limited, May 2024, sales of its potassium-competitive acid blocker, Takecab/Vocinti, reached 118.5 billion JPY for the fiscal year ended March 31, 2024, reflecting robust clinical adoption. Furthermore, manufacturers are targeting emerging regions to capitalize on unmet needs; according to Daewoong Pharmaceutical, August 2024, the company expanded its novel agent Fexuprazan into Latin America, targeting an anti-ulcer drug market valued at $300 million in Mexico, Chile, and Ecuador alone. These innovations provide clinicians with effective salvage options, thereby sustaining market value despite the challenges of antimicrobial resistance.

Download Free Sample Report

Key Market Challenges

The rising incidence of antimicrobial resistance presents a formidable barrier to the growth of the Global Duodenal Ulcer Treatment Market by fundamentally undermining the reliability of standard-of-care pharmaceutical regimens. As bacterial strains, particularly Helicobacter pylori, develop robust immunity to essential antibiotics, the clinical efficacy of traditional first-line therapies—typically comprising proton pump inhibitors combined with clarithromycin or metronidazole—diminishes significantly. This reduction in treatment success rates forces healthcare providers to abandon streamlined, high-volume prescription models in favor of more complex, longer-duration salvage therapies. Consequently, the predictability of pharmaceutical inventory turnover is disrupted, and the commercial viability of established drug combinations is threatened as clinicians hesitate to prescribe standard antibiotic packs without expensive susceptibility testing.

The severity of this market impediment is underscored by recent clinical data which highlights the extent of therapeutic failure. According to the American College of Gastroenterology, in 2024, resistance rates to clarithromycin were confirmed to equal or exceed 20 percent across all monitored regions in the United States. This statistical reality indicates that a substantial segment of the target patient population is now unresponsive to the most common empiric treatments. Such high levels of resistance create a volatile market environment where the consistent application of standard pharmaceutical products is no longer guaranteed, thereby stalling the momentum of the broader duodenal ulcer treatment sector.

Key Market Trends

The Proliferation of Fixed-Dose Combination Kits for H. pylori Eradication is reshaping the market by addressing the critical issue of patient non-adherence to complex multi-drug regimens. As resistance to standard clarithromycin-based triple therapies rises, pharmaceutical developers are introducing all-in-one capsules that combine antibiotics with acid suppressants to simplify dosage schedules and enhance bactericidal efficacy. This trend is rapidly gaining commercial traction as payers recognize the value of streamlined administration in preventing treatment failure and subsequent salvage therapies. According to RedHill Biopharma, August 2024, the company’s rifabutin-based fixed-dose combination, Talicia, has secured expanded formulary successes covering approximately 25 million lives in the United States, indicating a strong market shift towards simplified, resistance-focused eradication protocols.

Simultaneously, there is a distinct Shift Toward Minimally Invasive Endoscopic Therapeutic Interventions for managing ulcer-related complications such as upper gastrointestinal bleeding. Advanced hemostatic technologies, including through-the-scope clips and hemostatic powders, are replacing traditional surgical approaches, allowing clinicians to treat high-risk bleeding ulcers with greater precision and lower morbidity. The widespread adoption of next-generation visualization systems enhances the detection and treatment of these lesions, driving significant revenue growth in the device segment. According to Olympus Corporation, May 2024, the company’s GI Endoscopy business in North America grew by 20% year-over-year following the introduction of the EVIS X1 endoscopy system, underscoring the accelerating demand for advanced therapeutic visualization platforms in clinical practice.

Segmental Insights

The Proton Pump Inhibitors segment is anticipated to witness the fastest growth within the Global Duodenal Ulcer Treatment Market due to superior efficacy in reducing gastric acid production. Medical guidelines frequently recommend these medications as a primary therapy for accelerating healing and eradicating Helicobacter pylori infections. Furthermore, increased approvals of generic formulations by regulatory authorities such as the U.S. Food and Drug Administration have enhanced market accessibility for patients. This preference over alternative treatments, such as H2 antagonists, stems from a proven clinical track record in managing acid-peptic disorders effectively.

Regional Insights

North America leads the global duodenal ulcer treatment market, primarily driven by the high consumption of non-steroidal anti-inflammatory drugs which contributes to ulcer prevalence. The region benefits from a well-developed healthcare infrastructure and comprehensive reimbursement policies that ensure patient access to essential therapeutics. Furthermore, the market is strengthened by the strong presence of major pharmaceutical manufacturers and the rigorous product approval processes overseen by the US Food and Drug Administration. These factors collectively create a favorable environment for sustained market dominance across the United States and Canada.

Recent Developments

• In October 2025, HK inno.N Corp. announced the successful completion of a Phase 3 clinical trial evaluating the efficacy and safety of its drug K-CAB (tegoprazan) for the prevention of gastric and duodenal ulcers induced by long-term use of non-steroidal anti-inflammatory drugs (NSAIDs). The study, conducted across multiple medical institutions, demonstrated that the drug was non-inferior to lansoprazole in preventing ulcer development over a 24-week period. The company stated that these results would support an application to expand the drug's approved indications, further solidifying its position in the peptic ulcer treatment market.
• In April 2025, Daewoong Pharmaceutical Co., Ltd. officially launched its gastroesophageal reflux disease and anti-ulcer treatment, Fexuclue (fexuprazan), in India through a collaboration with Sun Pharmaceutical Industries Ltd. This launch allowed the company to enter the world's fourth-largest anti-ulcer drug market, positioning its potassium-competitive acid blocker against established proton pump inhibitors. The partnership with the largest pharmaceutical company in India was established to facilitate the distribution and commercialization of the treatment, addressing significant unmet medical needs in the management of acid-related conditions in the region.
• In September 2024, Jeil Pharmaceutical Co., Ltd. announced the official launch of Jaqbo (zastaprazan), a novel potassium-competitive acid blocker (P-CAB), in the South Korean market. Developed by its subsidiary Onconic Therapeutics, the drug entered the country’s substantial peptic ulcer treatment sector as the 37th domestically developed novel drug. The launch was supported by a co-promotion agreement with Dong-A ST to maximize market penetration. Jaqbo is designed to suppress gastric acid secretion rapidly and effectively, offering a new therapeutic option for acid-related disorders, including those affecting the duodenum.
• In August 2024, RedHill Biopharma Ltd. announced the commercial launch of Talicia (omeprazole magnesium, amoxicillin, and rifabutin) in the United Arab Emirates. This strategic expansion marked the first introduction of the drug in a territory outside the United States for the treatment of Helicobacter pylori infection, a primary cause of duodenal ulcers and gastric cancer. The company highlighted that the launch in the UAE was a significant milestone in its global strategy to address the high prevalence of H. pylori and the growing challenge of antibiotic resistance associated with clarithromycin-based therapies.

Key Market Players

• Takeda
• AstraZeneca
• Pfizer
• GlaxoSmithKline
• Novartis
• Bayer
• Sanofi
• Johnson & Johnson
• Sun Pharma
• Cipla

By Treatment	By Route Of Administration	By Distribution Channel	By Region
Proton Pump Inhibitors H2 Antagonists Antibiotics Other	Oral Parenteral	Retail Pharmacies Hospital Pharmacies Other	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Duodenal Ulcer Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Duodenal Ulcer Treatment Market, By Treatment:

• Proton Pump Inhibitors
• H2 Antagonists
• Antibiotics
• Other

• Duodenal Ulcer Treatment Market, By Route Of Administration:

• Oral
• Parenteral

• Duodenal Ulcer Treatment Market, By Distribution Channel:

• Retail Pharmacies
• Hospital Pharmacies
• Other

• Duodenal Ulcer Treatment Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE